Loading startup
Market data is refreshed once per day from public sources. Information may be incomplete or outdated — verify independently before making decisions. This is not investment advice.
DealFlow OS uses public web data and automated enrichment. Research may be incomplete, outdated, or incorrect. Verify important information before making investment or outreach decisions.
Evidence-bound summary — expand sections for movement, risks, and signals.
Memo snapshot · May 20, 2026, 6:08 PM
DealFlow OS uses public web data and automated enrichment. Research may be incomplete, outdated, or incorrect. Verify important information before making investment or outreach decisions.
Exin Therapeutics
Raised $500K across 1 funding round. Latest: $500K Pre-seed (Jan 2025). Investors: Y Combinator. (High).
Seed (YC)
Verified facts
+2 more in Recent movement below
Funding
Raised $500K across 1 funding round. Latest: $500K Pre-seed (Jan 2025). Investors: Y Combinator. (High).
Hiring
1 hiring‑related row(s); role‑spam risk if mostly generic boards (Low).
GitHub
No GitHub‑linked evidence indexed (Low).
Product / news
3 product/news‑styled row(s); headline risk without filings (High).
Traffic / social
No traffic/social evidence indexed (Low).
Winter 2025 batch; AI drug discovery for neurotherapeutics using in-house mouse studies and multimodal ML.
No open roles indexed yet.
HTTP 404
HTTP 404
HTTP 404
HTTP 404
The score is an algorithmic estimate based on observed public company-level signals. It may be incomplete, stale, or inaccurate and is not investment, legal, tax, or business advice.
DealFlow score momentum
More runs will build history.
The score is an algorithmic estimate based on observed public company-level signals. It may be incomplete, stale, or inaccurate and is not investment, legal, tax, or business advice.
Latest momentum signal per category. Expand a card to inspect raw payloads.
Source types found
Strongest / recent news-style rows
Exin Therapeutics | Y Combinator
Wed, May 20, 06:08 PM · confidence 88%high quality
https://www.ycombinator.com/companies/exin-therapeuticsLaunch YC: Exin Therapeutics
Wed, May 20, 06:08 PM · confidence 85%medium quality
https://www.ycombinator.com/launches/Md0-exin-therapeutics-an-ai-discovery-platform-for-neurotherapeuticsNewest first · 6 event(s)
Official site for AI-driven neurotherapeutics discovery.
Winter 2025 batch; AI drug discovery for neurotherapeutics using in-house mouse studies and multimodal ML.
Source: Blog / news
13th Jan. 2025. - Exin Therapeutics officially launches!
Source: Careers
We are hiring the lab team for our new R&D facility in Metro Manila, Philippines. The Manila lab will be the cornerstone of our experimental efforts, enabling ultra large-scale in vivo neuroscience and data generation to power the discovery of novel neurotherapeutics. We have openings across a
Source: Blog / news
Lowering the cost of data, raising the scale of discovery.
Launch post on circuit-level approach and multimodal AI for preclinical R&D.
1 row(s)
Official site for AI-driven neurotherapeutics discovery.
https://www.exintherapeutics.com/1 row(s)
Launch post on circuit-level approach and multimodal AI for preclinical R&D.
https://www.ycombinator.com/launches/Md0-exin-therapeutics-an-ai-discovery-platform-for-neurotherapeutics1 row(s)
Winter 2025 batch; AI drug discovery for neurotherapeutics using in-house mouse studies and multimodal ML.
https://www.ycombinator.com/companies/exin-therapeutics1 row(s)
Source name: Careers
We are hiring the lab team for our new R&D facility in Metro Manila, Philippines. The Manila lab will be the cornerstone of our experimental efforts, enabling ultra large-scale in vivo neuroscience and data generation to power the discovery of novel neurotherapeutics. We have openings across a
https://www.exintherapeutics.com/careers2 row(s)
Source name: Blog / news
13th Jan. 2025. - Exin Therapeutics officially launches!
https://www.exintherapeutics.com/newsSource name: Blog / news
Lowering the cost of data, raising the scale of discovery.
https://www.exintherapeutics.com/blogSign in as an active team member to view private notes, watchlist controls, transcript evidence, and interaction history.